CT-03 Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis | Zendy

AI Assistant Blog Pricing

CT-03 Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.